Inhibrx EPS - Earnings per Share 2020-2022 | INBX

Inhibrx eps - earnings per share from 2020 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Inhibrx Annual EPS
2021 $-2.15
2020 $-3.01
2019 $-2.83
Inhibrx Quarterly EPS
2022-06-30 $-0.97
2022-03-31 $-0.80
2021-12-31 $-0.55
2021-09-30 $-0.54
2021-06-30 $-0.55
2021-03-31 $-0.51
2020-12-31 $-0.14
2020-09-30 $-0.77
2020-06-30 $-0.99
2020-03-31 $-1.11
2019-12-31 $0.00
2019-09-30 $-1.11
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.958B $0.007B
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00